Angiographic assessment of variants of basal vein of Rosenthal in idiopathic subarachnoid hemorrhage

Karataş, Ayşe; Çakır, Volkan; Sevin, Ertan; Ballı, Ömür; Feran, Hamit

doi:10.1016/j.pjnns.2015.05.001

Cited by 5 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The basal vein, which is located in the ambient cistern medially and cranially to the posterior cerebral artery, drains large areas of ventricular walls of one hemisphere [ 28 , 29 ]. Because their identification rate is greater than 90% and their location is constant, BVRs are ideal targets for assessment of venous blood flow by TCD [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Argatroban Increased the Basal Vein Drainage and Improved Outcomes in Acute Paraventricular Ischemic Stroke Patients

Liu

et al. 2020

Med Sci Monit

View full text Add to dashboard Cite

Background Since venous drainage in acute arterial ischemic stroke has not been thoroughly researched, we evaluate the effect of argatroban, a selective direct thrombin inhibitor, as a therapy to increase the rate of basal vein Rosenthal (BVR) drainage and improve patients’ post-stroke outcomes. Material/Methods In this multicenter clinical trial, 60 eligible patients at 4.5 to 48 hours after the stroke onset were recruited. After being randomly allocated into 2 groups, they were treated with standard therapy either alone or with argatroban. Results Compared to the contralateral brain hemisphere, the mean flow velocity (MFV) in BVR drainage was significantly reduced in the stroke-afflicted ipsilateral hemisphere. After treatment with argatroban for 7 days, the MFV from BVR of the ipsilateral hemisphere in the argatroban treated group was significantly increased when compared to the control group. At 90 days after the onset of stroke, the MFV of BVR in the ipsilateral hemisphere was similar in both groups. Compared with controls, the argatroban-treated patients had smaller lesions from baseline to 7 days. Argatroban also improved National Institutes of Health Stroke Scale (NIHSS) scores on day 7 after the onset of stroke. Furthermore, the argatroban group’s neurological functions were superior to those of their untreated counterparts after 90 days. No difference was found in the incidence of adverse reactions between the 2 groups. Conclusions These observations indicate that vein drainage change may contribute to the acute phase of brain edema and the outcomes of ischemic stroke patients. Clinical Trial Registration URL- http://www.chictr.org Unique identifier: ChiCTR-IPR-16008663

show abstract

Section: Discussionmentioning

confidence: 99%